Sitemap Home argenx Group Shareholder Letter 2024 In Brief 2025 Outlook Company Profile Strategy and Objectives Our Products and Product Candidates VYVGART efgartigimod Development efgartigimod Indications empasiprubart Development ARGX-119 Development ARGX-213, ARGX-121, ARGX-220 and ARGX-109 Development Immunology Innovation Program Collaborations and licenses Manufacturing and Supply Intellectual Property Regulation Licensure and Regulation of Biologics in the U.S. Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK Regulation and Procedures Governing Approval of Medicinal Products in Japan Coverage, Pricing and Reimbursement Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S. Healthcare Law and Regulation Healthcare Reform Environmental Issues which may Influence the Use of our Material Fixed Assets Documents on display Risk Factors Summary Commercialization Development and Clinical Testing Dependence on Third Parties Other Government Regulations Financial Position Business and Industry Intellectual Property Organization and Operations American Depository Shares Being a Foreign Private Issuer or a Dutch Company Corporate Governance Dutch Corporate Governance Code Management Structure General Statement of the Board of Directors Board of Directors Non-Executive Directors Senior Management Team Conflict-of-Interest and Related Party Transactions Code of Business Conduct and Ethics Report of the Non-Executive Directors Remuneration Report and Compensation Statement Letter of the Chairperson of the Remuneration and Nomination Committee Introduction 2024 Remuneration Application of the 2021 Remuneration Policy in 2024 Remuneration of Other Members of the Senior Management Team Non-Executive Director Remuneration Pay Ratios Other Disclosures Peer group selection Looking Forward Summary of Named Executive Officer Remuneration Summary of other members of the Senior Management Team Summary of Non-Executive Director Equity compensation Corporate Governance Share Ownership Insider Trading Cybersecurity Risk Appetite & Control Share Capital Legal Information on the Company Share Capital Share Classes and Principal Shareholders Limitations on the right to hold securities General Meeting, Voting Rights and Admission Anti-Takeover Provisions Change of Control Exchange Controls Amendments of Articles of Association Transparency Directive Dutch Financial Reporting Supervision Act Dividends and Other Distributions Right to a surplus in the event of a liquidation Material Modifications to the Rights of Security Holders and Use of Proceeds Enforcement of civil liabilities Controls and Procedures Financial Calendar 2025 Financial Review Overview Basis of presentation Critical Accounting Judgements and Major Sources of Estimation Uncertainty Results of Operation Liquidity and Capital Resources Research and development, patents and licenses Trend information Off-Balance Sheet Arrangements Contractual Obligations Information Regarding the Independent Auditor Material Contracts and Related Party Transactions Employees Insurance Legal and Arbitration Proceedings Taxation Financial Statements Consolidated Financial Statements Consolidated Statements of Financial Position Consolidated Statements of Profit or Loss Consolidated Statements of Comprehensive Income or Loss Consolidated Statements of Cash Flows Consolidated Statements of Changes in Equity Notes to the Consolidated Financial Statements 1. General Information about the Company 2. Material Accounting Policy Information 3. Critical accounting judgments and major sources of estimation uncertainty 4. Property, Plant and Equipment 5. Intangible Assets 6. Other Non-Current Assets 7. Inventories 8. Prepaid Expenses (Current) 9. Trade and Other Receivables 10. Financial Assets – Current 11. Cash and Cash Equivalents 12. Share Capital and Share Premium 13. Share-Based Payments 14. Trade and Other Payables 15. Collaboration Revenue 16. Other Operating Income 17. Segment Reporting 18. Research and Development Expenses 19. Selling, General and Administrative Expenses 20. Personnel Expenses 21. Leases 22. Financial Result and Exchange Gains/(Losses) 23. Income taxes 24. Earnings per Share 25. Financial Risk Management 26. Related Party Transactions 27. Contingencies 28. Commitments 29. Audit Fees 30. Overview of Consolidation Scope 31. Events After the Balance Sheet Date Company Financial Statements Signatures of Executive and Non-Executive Directors Company Financial Statements for argenx SE Notes to the Company Financial Statements Other information Provision in the articles of association governing the appropriation of results Independent Auditor’s report Independent Auditor’s Report on the Sustainability Statement Non-Financial Information Sustainability Statement Sustainability Strategy Environment Social Industry Specific Disclosures Governance Other Considerations Appendix Patient Stories Glossary Cross Reference table for annual reporting requirements Management Confirmations Definitions
